UK markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
27.81+0.11 (+0.40%)
At close: 04:00PM EDT
27.86 +0.05 (+0.18%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close27.70
Open27.86
Bid27.83 x 2900
Ask27.77 x 2200
Day's range27.52 - 27.91
52-week range25.20 - 40.37
Volume45,367,552
Avg. volume41,423,372
Market cap157.475B
Beta (5Y monthly)0.57
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.68 (6.04%)
Ex-dividend date09 May 2024
1y target estN/A
All
News
  • Business Wire

    Pfizer Reports First-Quarter 2024 Results

    NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).

  • Business Wire

    TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

    COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti

  • Business Wire

    FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

    NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.